To include your compound in the COVID-19 Resource Center, submit it here.

Arch backs Vizgen’s RNA imaging platform with $14M series A

Arch thinks Vizgen’s technology could improve transcriptome imaging, provide more insight into disease biology

Arch Venture Partners is adding to its portfolio of life science tool companies by co-leading a $14 million series A for Vizgen, which is developing technology the firm thinks can overcome capacity limitations of current single-cell RNA imaging technology.

Northpond Ventures also led the untranched round; the firm’s Sharon Kedar will join the board.

Arch’s Keith Crandell told BioCentury the firm has

Read the full 621 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE